Ligand Terminates Long-Term Lease Obligation
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand and Organon Mutually Terminate Collaboration and License Agreement
Ligand to Hold Second Quarter Results Conference Call on August 3
Ligand Licenses Patents for Desulfated Heparin Technology to ParinGenix
Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders
CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
Ligand Pharmaceuticals Announces First Quarter Results
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
Ligand Pharmaceuticals and The Rockefeller University Enter Settlement Agreement and Mutual Release
Ligand Earns $1 Million Milestone Payment on Progress of Drug Candidate for Alzheimer's Disease
Ligand Enters into Screening Agreement with Trevena
Ligand to Present at BIO CEO and Investor Conference on February 9
Ligand Announces Phase IIb Results With DARA
